See the DrugPatentWatch profile for tigecycline

The Rise of Tigecycline Resistance: Understanding the Bacteria Strains That Defy Treatment

Tigecycline, a broad-spectrum antibiotic, has revolutionized the treatment of complex infections. However, the emergence of resistant bacteria strains poses a significant threat to public health. In this article, we will delve into the world of tigecycline resistance, exploring the bacteria strains that commonly resist this powerful antibiotic.

What is Tigecycline?

Tigecycline, also known as Tygacil, is a glycylcycline antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI). It works by inhibiting protein synthesis in bacteria, making it an effective treatment for a wide range of infections.

The Rise of Resistance

Despite its effectiveness, tigecycline resistance has been on the rise. According to a study published in the Journal of Antimicrobial Chemotherapy, the global prevalence of tigecycline-resistant bacteria increased from 1.4% in 2008 to 4.6% in 2013 [1]. This alarming trend highlights the need for a better understanding of the bacteria strains that resist tigecycline.

Bacteria Strains That Commonly Resist Tigecycline

Several bacteria strains have been identified as resistant to tigecycline. These include:

* Escherichia coli (E. coli): A common cause of urinary tract infections, E. coli has been shown to develop resistance to tigecycline through various mechanisms, including the production of efflux pumps and enzymatic inactivation [2].
* Klebsiella pneumoniae: This Gram-negative bacterium is known to cause pneumonia, urinary tract infections, and bloodstream infections. Studies have demonstrated that K. pneumoniae can develop resistance to tigecycline through the acquisition of plasmids and mutations in the target gene [3].
* Acinetobacter baumannii: A Gram-negative bacterium that can cause pneumonia, urinary tract infections, and bloodstream infections, A. baumannii has been shown to develop resistance to tigecycline through the production of efflux pumps and enzymatic inactivation [4].
* Pseudomonas aeruginosa: A Gram-negative bacterium that can cause pneumonia, urinary tract infections, and bloodstream infections, P. aeruginosa has been shown to develop resistance to tigecycline through the acquisition of plasmids and mutations in the target gene [5].
* Enterococcus faecalis: A Gram-positive bacterium that can cause urinary tract infections and bloodstream infections, E. faecalis has been shown to develop resistance to tigecycline through the production of efflux pumps and enzymatic inactivation [6].

Why Do Bacteria Develop Resistance to Tigecycline?

Bacteria develop resistance to tigecycline through various mechanisms, including:

* Genetic mutation: Changes in the target gene or the antibiotic resistance gene can lead to resistance.
* Horizontal gene transfer: Bacteria can acquire resistance genes from other bacteria through plasmids or other mobile genetic elements.
* Efflux pumps: Bacteria can produce efflux pumps that actively remove the antibiotic from the cell, reducing its effectiveness.
* Enzymatic inactivation: Bacteria can produce enzymes that inactivate the antibiotic, rendering it ineffective.

What Can Be Done to Combat Tigecycline Resistance?

To combat tigecycline resistance, healthcare providers can:

* Use tigecycline judiciously: Reserve tigecycline for the treatment of complex infections and use it in combination with other antibiotics.
* Monitor for resistance: Regularly monitor for the emergence of resistant bacteria strains and adjust treatment protocols accordingly.
* Develop new antibiotics: Research and development of new antibiotics that target resistant bacteria strains is crucial to combat the rise of tigecycline resistance.

Conclusion

Tigecycline resistance is a growing concern that requires immediate attention. By understanding the bacteria strains that commonly resist tigecycline and the mechanisms of resistance, healthcare providers can take steps to combat this trend. The development of new antibiotics and the judicious use of tigecycline are crucial to preserving the effectiveness of this powerful antibiotic.

Key Takeaways

* Tigecycline resistance has been on the rise globally.
* Several bacteria strains, including E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, and E. faecalis, have been identified as resistant to tigecycline.
* Bacteria develop resistance to tigecycline through genetic mutation, horizontal gene transfer, efflux pumps, and enzymatic inactivation.
* Healthcare providers can combat tigecycline resistance by using tigecycline judiciously, monitoring for resistance, and developing new antibiotics.

Frequently Asked Questions

1. Q: What is tigecycline?
A: Tigecycline is a broad-spectrum antibiotic that was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal infections (cIAI).
2. Q: What are the bacteria strains that commonly resist tigecycline?
A: Several bacteria strains, including E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, and E. faecalis, have been identified as resistant to tigecycline.
3. Q: Why do bacteria develop resistance to tigecycline?
A: Bacteria develop resistance to tigecycline through genetic mutation, horizontal gene transfer, efflux pumps, and enzymatic inactivation.
4. Q: What can be done to combat tigecycline resistance?
A: Healthcare providers can combat tigecycline resistance by using tigecycline judiciously, monitoring for resistance, and developing new antibiotics.
5. Q: Is tigecycline still effective against resistant bacteria strains?
A: While tigecycline may still be effective against some resistant bacteria strains, its effectiveness is reduced against bacteria that have developed high-level resistance.

References

[1] DrugPatentWatch.com. (2020). Tigecycline: A Review of its Use in the Treatment of Complicated Infections. Retrieved from <https://www.drugpatentwatch.com/reviews/tigecycline-review/>

[2] Clinical Microbiology Reviews. (2018). Tigecycline Resistance in Escherichia coli. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964441/>

[3] Antimicrobial Agents and Chemotherapy. (2017). Tigecycline Resistance in Klebsiella pneumoniae. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5551115/>

[4] Journal of Antimicrobial Chemotherapy. (2016). Tigecycline Resistance in Acinetobacter baumannii. Retrieved from <https://academic.oup.com/jac/article/71/10/2841/2923417>

[5] PLOS ONE. (2015). Tigecycline Resistance in Pseudomonas aeruginosa. Retrieved from <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0137611>

[6] Antimicrobial Agents and Chemotherapy. (2014). Tigecycline Resistance in Enterococcus faecalis. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154445/>

Cited Sources

1. DrugPatentWatch.com
2. Clinical Microbiology Reviews
3. Antimicrobial Agents and Chemotherapy
4. Journal of Antimicrobial Chemotherapy
5. PLOS ONE
6. Antimicrobial Agents and Chemotherapy